

## CURRICULUM VITAE

### Steven M. Smith, PharmD, MPH, BCPS, ASH-CHC

---

---

#### **GENERAL INFORMATION**

Address: Department of Pharmacotherapy & Translational Research  
University of Florida  
P.O. Box 100486  
Gainesville, Florida 32610-0486

Office: 352-273-5134  
Fax: 352-273-6242  
Email: [ssmith@cop.ufl.edu](mailto:ssmith@cop.ufl.edu)

Present Position: Assistant Professor of Pharmacy and Medicine  
Department of Pharmacotherapy & Translational Research  
Department of Community Health & Family Medicine  
Colleges of Pharmacy and Medicine  
University of Florida

#### **EDUCATION & TRAINING**

*Associate of Arts*, Santa Fe College, Gainesville, FL, 2003

*Doctor of Pharmacy*, University of Florida, College of Pharmacy, Gainesville, FL, 2007

*Master of Public Health*, University of Florida, College of Public Health and Health Professions, Gainesville, FL, 2011

*Hospital Practice Residency*, North Florida/South Georgia Veterans Health System, Gainesville, FL;  
Director: Mark Burlingame, PharmD, BCPS, 2007-2008

*Postdoctoral Fellowship in Family Medicine Clinical Research*, Departments of Pharmacotherapy & Translational Research and Community Health & Family Medicine, Colleges of Pharmacy and Medicine, University of Florida, Gainesville, FL; Director: John G. Gums, PharmD, FCCP, 2008-2011

*Advanced Postgraduate Program in Clinical Investigation (APPCI) Fellowship*, University of Florida, Gainesville, FL; Directors: Marian C. Limacher, MD, FACC, and Nabih Asal, PhD, FACE; Clinical Research Curriculum Award K30RR022258 from the National Center for Research Resources, 2009-2011

*Clinical Faculty Scholars Program*, Colorado Clinical and Translational Sciences Institute (CCTSI), University of Colorado, Aurora, CO; Program Mentors: Anne Libby, PhD and Allen Prochazka, MD, MSc; 2013-2014

*Graduate Certificate in Biomedical Informatics*, University of Florida, Gainesville, FL, 2016 – present

## **PROFESSIONAL CREDENTIALS**

- Licensure: Florida: PS43084 (2007 – present; active)  
Colorado: PHA-19305 (2011 – present; inactive)
- Certifications: Board-Certified Pharmacotherapy Specialist (BCPS), #312178, 2012 – 2019  
American Society of Hypertension Certified Hypertension Clinician (ASH-CHC), 2016 – 2026

## **ACADEMIC APPOINTMENTS**

- 2016 – present *Assistant Professor (tenure-track)*, Department of Pharmacotherapy & Translational Research, College of Pharmacy, University of Florida, Gainesville, FL
- 2016 – present *Assistant Professor (tenure-track)*, Department of Community Health & Family Medicine, College of Medicine, University of Florida, Gainesville, FL
- 2014 – 2016 *Clinical Assistant Professor*, Department of Pharmacotherapy & Translational Research, College of Pharmacy, University of Florida, Gainesville, FL
- 2014 – 2016 *Clinical Assistant Professor*, Department of Community Health & Family Medicine, College of Medicine, University of Florida, Gainesville, FL
- 2011 – 2014 *Assistant Professor*, Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado
- 2008 – 2011 *Postdoctoral Fellow & Clinical Instructor*, Departments of Pharmacotherapy & Translational Research and Community Health & Family Medicine, Colleges of Pharmacy and Medicine, University of Florida
- 2008 – 2011 *Clinical Instructor*, Physician's Assistant Program, College of Medicine, University of Florida

## **PROFESSIONAL PRACTICE EXPERIENCE**

- 2014 – 2016 *Clinical Pharmacist*, Community Health & Family Medicine, University of Florida, Gainesville, FL
- 2012 – 2014 *Director*, Pharmacist-Physician Collaborative Hypertension Clinic, University Medicine Lowry, University of Colorado Hospital, Aurora, CO
- 2011 – 2014 *Clinical Pharmacist*, University Medicine Lowry, University of Colorado Hospital, Aurora, CO
- 2008 – 2011 *Postdoctoral Fellow*, Departments of Pharmacotherapy & Translational Research and Community Health & Family Medicine, University of Florida, Gainesville, FL
- 2009 – 2011 *Florida Medicaid Beneficiary Auditor/Reviewer*, Florida Agency for Health Care Administration (AHCA), Tallahassee, FL

- 2008 – 2011      *Research Pharmacist*, North Florida/South Georgia Veterans Health System, Gainesville, FL
- 2008 – 2010      *Health Information Provider*, Disease Prevention and Health Promotion Program, Suwannee River Area Health Education Center (SRAHEC), Alachua, FL
- 2007 – 2008      *Staff Pharmacist* (part time, intermittent), North Florida/South Georgia Veterans Health System, Gainesville, FL
- 2007 – 2008      *Pharmacy Resident*, North Florida/South Georgia Veterans Health System, Gainesville, FL

## **HONORS & AWARDS**

- 2015              *2015 New Investigator Award*, American College of Clinical Pharmacy (this award recognizes the ACCP member <6 years since completion of training whose research program is especially noteworthy in theme and productivity)
- 2014 – 2016      *Institute of Medicine (now National Academy of Medicine) Anniversary Fellow in Pharmacy*, Institute of Medicine, The National Academies of Science, Washington, D.C. (this 2-year IOM fellowship is awarded to only one pharmacist nationwide)
- 2014              *The “Great Eight” Best Papers* finalist and second runner-up, American College of Clinical Pharmacy 2014 Annual Meeting

## **GRANT & RESEARCH ACTIVITY**

### **Current Funding**

Source: Pilot Grants program, Clinical & Translational Science Institute, University of Florida  
Title: “Hypertension prevalence and disparities in the OneFlorida Data Trust”  
Time Period: 10/10/2016 – 10/09/2017  
Total Direct: \$13,835  
Role: Principal Investigator

Source: National Academy of Medicine  
Unrestricted Research Grant for NAM Fellowship  
Time Period: 10/20/2014 – 10/20/2016  
Total Direct: \$25,000  
Role: Principal Investigator

Source: NIH/NHLBI (R18 HL116259)  
Title: “MEDication Focused Outpatient Care for Underutilization of Secondary Prevention (MED-FOCUS)”  
Time Period: 4/1/2014 – 3/31/2019  
Role: Site Investigator

Source: NIH/NHGRI (U01 HG007269)  
Title: “Genomic Medicine Implementation: The Personalized Medicine Program (PMP): Genotyping in Family Medicine Clinics”  
Time Period: 1/1/2015 – 12/31/2016  
Role: Co-Investigator

Source: PROSPER Grant, College of Pharmacy, University of Florida  
Title: "Enhancing Research Data Access and Availability to University of Florida College of Pharmacy Faculty"  
Time Period: 8/1/2016 – 7/30/2017  
Total Direct: \$40,000  
Role: Co-Investigator

**Submitted Grants** (pending)

Source: UF CTSI KL2 (KL2 Scholars Program)  
Title: "Combining Biomedical Informatics and Pharmacoepidemiology to Improve Antihypertensive Drug Selection using Real World EHR Data"  
Time Period: 04/01/2017-03/31/2019  
Role: Principal Investigator

Source: NHLBI/NIH (1K01HL138172)  
Title: "Advancing Personalized Hypertension Care through Big Data Science"  
Time Period: 02/01/2017-01/31/2022  
Total Direct: \$524,425  
Role: Principal Investigator

**Completed Grants** (reverse chronological order)

Source: UF Women's Health / Sex & Gender Differences in Health Open Access Publishing Fund  
Title: "Cardiovascular and Mortality Risk of Apparent Resistant Hypertension in Women With Suspected Myocardial Ischemia: A Report From the NHLBI-Sponsored WISE Study"  
Time Period: 08/2014  
Total Direct: \$1,500  
Role: Principal Investigator

Source: ALSAM Foundation  
Title: "Patient-Perceived Treatment Burden and Medication Non-adherence"  
Time Period: 7/1/2013 – 2/7/2014  
Total Direct: \$150,000  
Role: Principal Investigator

Source: Colorado Health Foundation  
Title: "Pharmacist Managed Medicare Outreach in Primary Care: Lowering Costs and Improving Health Outcomes"  
Time Period: 10/1/2012 – 2/7/2014  
Total Direct: \$166,020  
Role: Co-Principal Investigator (PI: K Trinkley)

Source: University of Colorado Hospital / University of Colorado School of Medicine  
Title: "Physician-Pharmacist Collaborative Hypertension Clinic"  
Time Period: 9/1/2012 – 10/31/2013  
Total Direct: \$25,000  
Role: Principal Investigator

Source: Colorado Health Foundation  
Title: "An academic model for providing adult primary care pharmacy consult services"  
Time Period: 9/1/2011 – 8/30/2012  
Total Direct: \$209,724  
Role: Co-investigator (PI: G Moore)

Source: NIH, National Heart Lung and Blood Institute, R01 HL091841  
Title: "A Collaborative Model to Improve BP Control and Minimize Racial Disparities NOW (CAPTION)"  
Time Period: 11/1/2008 – 6/30/2011  
Amount: \$6,738,456 (direct); \$9,296,523 (total); \$47,900 (total to site)  
Role: Site Principal Investigator (Trial PI: B Carter)

Source: Sanofi-aventis  
Title: "Venous Thromboembolism Project (VTEProject)"  
Time Period: 1/1/2010 – 6/30/2011  
Amount: \$404,300 (direct); \$509,418 (total)  
Role: Co-Principal Investigator (PI: J Gums)

Source: Ortho-McNeil Janssen Pharmaceuticals, Inc.  
Title: "Infectious Disease Outcomes Project (iDOP)"  
Time Period: 5/1/2009 – 6/30/2011  
Amount: \$295,000 (direct); \$371,700 (total)  
Role: Co Investigator (PI: J Gums)

Source: Agency for Healthcare Research and Quality  
Title: "Establishing Benchmarks for the Medical Office Survey on Patient Safety (SOPS)"  
Time Period: 4/1/2009 – 5/30/2009  
Amount: \$200 (total to site)  
Role: Site Principal Investigator (PI: G Kuo)

Source: Wyeth Pharmaceuticals  
Title: "Postdoctoral Research Project: Antimicrobial Resistance Management"  
Time Period: 1/1/2009 – 6/30/2011  
Amount \$13,500 (direct)  
Role: Principal Investigator

**PUBLICATIONS** (reverse chronological order; underline denotes student or postdoc; † denotes senior/corresponding author; the most up-to-date list of journal articles can be accessed [here.](#))

### Original Research

1. Hwang AY, Dave C, **Smith SM**†. Trends in antihypertensive medication use among U.S. patients with resistant hypertension, 2008-2014. *Hypertension* 2016;68:1349-54.
2. **Smith SM**, Huo T, Gong Y, Handberg E, Gulati M, Bairey Merz CN, Pepine CJ, Cooper-DeHoff RM. Mortality risk associated with resistant hypertension among women: Analysis from three prospective cohorts encompassing the spectrum of women's heart disease. *J Women's Health* 2016;25(10):996-1003.
3. Carris NW, Hwang AY, **Smith SM**, Taylor JR, Sando K, Powell J, Rosenberg EI, Zumberg MS, Gums JG, Dietrich EA, Vogel Anderson K. Patient satisfaction with extended-interval warfarin monitoring. *J Thromb Thrombolysis* 2016;42(4):486-493.
4. **Smith SM**, Carris NW, Dietrich ED, Gums JG, Uribe L, Coffey C, Gums TH, Carter BL. Physician-pharmacist collaboration versus usual care in treatment-resistant hypertension. *J Am Soc Hypertens* 2016;10(4):307-17.
5. Carris NW, Ghuschyan V, Libby AM, **Smith SM**†. Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives. *J Hum Hypertens* 2016;30:191-6.

6. **Smith SM**, Hasan M, Huebschmann AG, Penaloza R, Schorr-Ratzlaff W, Sieja A, Roscoe N, Trinkley KE. Physician acceptance of a physician-pharmacist collaborative treatment model for hypertension management in primary care. *J Clin Hypertens (Greenwich)* 2015;17(9):686-691.
7. **Carris NW**, Spinelli A, Pierini D, Taylor J, Anderson K, Sando K, Powell J, Rosenberg E, Zumberg M, **Smith SM**, Gums JG, Dietrich E. Feasibility of extended-interval follow-up for patients receiving warfarin. *Cardiovasc Ther* 2015;33:98-103.
8. Rosenwasser R, Shah NK, **Smith SM**, Wen X, Gong Y, Nichols WW, Turner S, Chapman AB, Boerwinkle E, Johnson JA, Epstein BJ. Baseline predictors of central aortic blood pressure: A PEAR substudy. *J Am Soc Hypertens* 2014;8(3):152-8.
9. **Smith SM**, Huo T, Johnson BD, Vittner V, Kelsey SF, Thompson DV, Bairey Merz CN, Pepine CJ, Cooper-DeHoff RM. Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: A report from the NHLBI-sponsored WISE study. *J Am Heart Assoc* 2014;3:e000660.
10. **Smith SM**, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, Bavry AA, Pepine CJ, Cooper-DeHoff RM. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. *J Hypertens* 2014;32:635-43.
11. **Smith SM**, Campbell JD. Cost-effectiveness of renin-guided treatment of hypertension. *Am J Hypertens* 2013;26:1303-10. (Chosen as "Editor's Choice" for this issue)
12. Evans G, Sutton DR, Dajani LH, Magee JS, Silva RA, Roura MF, Wadud K, Purcell JA, Travaglini S, Segel SA, Sultan S, Roffman MS, Ayad SS, Borja-Hart NL, **Smith SM**. A novel endocrinology-based wellness program to reduce medication expenditures and improve glycemic outcomes. *Diabetes Metab Syndr* 2013;7(2):87-90.
13. **Smith SM**, Gong Y, Turner ST, Cooper-DeHoff RM, Beitelshes AL, Chapman AB, Boerwinkle E, Bailey K, Johnson JA, Gums JG. Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. *Am J Hypertens* 2012;25:359-65.
14. Motycka C, Kesgen C, **Smith SM**, Alvarez E, Jones K. Potential benefits of warfarin monitoring by a clinical pharmacist in a long term care facility. *J Thromb Thrombolysis* 2012;33:173-7.
15. Shah NK, **Smith SM**, Nichols WW, Lo MC, Ashfaq U, Satish P, Johnson JA, Epstein BJ. Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: A comparison with atenolol (CENTRAL Study). *J Clin Hypertens (Greenwich)* 2011;13:917-24.
16. **Smith SM**, Anderson SD, Wen S, Gong Y, Turner ST, Cooper-DeHoff RM, Schwartz GL, Bailey K, Chapman A, Hall KL, Feng H, Boerwinkle E, Johnson JA, Gums JG. Thiazide-induced hyperglycemia is not related to hypokalemia: Results from the Pharmacogenomic Evaluation of Antihypertensive Response (PEAR) study. *Pharmacotherapy* 2009;29(10):1157-65.

Submitted:

17. **Smith SM**, Schroeder A, Hosokawa P, Saseen JJ, Metz K, Hirsch J, Libby AM. Comparing medication regimen complexity in patients with hypertension, diabetes, or both. Submitted to *Journal of Clinical Pharmacy and Therapeutics*, 2016.
18. Wokhlu A, Gong Y, **Smith SM**, Handberg EM, Elgendy IY, Bavry AA, Cooper-DeHoff RM, Pepine CJ. Mortality Implications Associated with Lower Diastolic Blood Pressure When Systolic Pressure is Reduced to New Goals: Long-term Follow-up of Hypertensive Patients with Coronary Artery Disease in US Cohort of

International Verapamil (SR)-Trandolapril Study (INVEST). Submitted to *Journal of American College of Cardiology*, 2016.

19. Tsai T, Kroehl ME, **Smith SM**, Thompson AM, Dai I, Trinkley KE. Efficacy and safety of twice- versus once-daily dosing of lisinopril for hypertension. Submitted to *Journal of Clinical Hypertension*, 2016.

#### Review Articles (peer-reviewed)

1. Carris NW, **Smith SM**†. Quality of life in treatment-resistant hypertension. *Curr Hypertens Rep* 2015;17(8):578. Invited Review.
2. VanderWeide L, **Smith SM**, Trinkley KE. A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia. *J Clin Pharm Ther* 2015;40(1):1-6.
3. **Smith SM**. Epidemiology, prognosis, and treatment of resistant hypertension. *Pharmacotherapy* 2013;33(10):1071-86.
4. Nuffer W, **Smith SM**, Trinkley KE. Integrating “virtual reality” to expand the public health role of community pharmacists. *J Am Pharm Assoc* 2013;53:152-8.
5. **Smith SM**, Meyer M, Trinkley KE. Phentermine/topiramate (Qsymia®) for the treatment of obesity. *Ann Pharmacother* 2013;47:340-9.
6. Bovio J, **Smith SM**†, Gums JG. Dabigatran etexilate: A novel oral thrombin inhibitor for thromboembolic disease. *Ann Pharmacother* 2011;45:603-14.
7. **Smith SM**, Gums JG. Antivirals for influenza: Strategies for use in pediatrics. *Pediatr Drugs* 2010;12(5):285-99.
8. Epstein BJ, **Smith SM**, Choksi R. Recent changes in the landscape of combination RAS blockade. *Expert Rev Cardiovasc Ther* 2009;7(11):1373-84.
9. **Smith SM**, Gums JG. Fexofenadine: Biochemical, pharmacodynamics and pharmacokinetic properties and its unique role in allergic disorders. *Expert Opin Drug Metab Toxicol* 2009;5(7):813-822.

#### Editorials, Commentaries, & Letters to the Editor

1. **Smith SM**. Resistant hypertension and susceptible outcomes: Exploring the benefits of aggressive blood pressure control. *J Clin Hypertens (Greenwich)* 2015;18(1):40-42. (Invited Commentary).
2. **Smith SM**, Cooper-DeHoff RM. Home blood pressure monitoring with patient-initiated antihypertensive drug titration reduces blood pressure in high-risk patients with hypertension. *Evid Based Med* 2015;20(2):58. (Invited Commentary).
3. **Smith SM**, Pepine CJ, Cooper-DeHoff RM. Reply to “Resistant hypertension revisited: Definition and true prevalence.” *J Hypertens* 2014;32:1547.
4. **Smith SM**. Thiazide diuretics. *N Engl J Med* 2010;362(7):659-60.

#### Book Chapters

1. Hwang AY, **Smith SM**, Gums JG. Cushing Syndrome. In: Schwinghammer TL, Koehler JM, Borchert JS, Park S, Slain DS, eds. Pharmacotherapy Casebook: A Patient-Focused Approach. 10<sup>th</sup> ed. New York, NY: McGraw-Hill; 2017 [in press].
2. Hwang AY, **Smith SM**, Gums JG. Hypothalamic, Pituitary and Adrenal Diseases. In: Tisdale JE and Miller DA. Drug-Induced Diseases: Prevention, Detection and Management. 3<sup>rd</sup> ed. Bethesda, MD: American Society of Health-System Pharmacists; 2016 [in press].
3. Hwang AY, **Smith SM**, Gums JG. Adrenal Gland Disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach. 10<sup>th</sup> ed. New York, NY: McGraw-Hill; 2016 [in press].
4. **Smith SM**, Pepine CJ. Hypertension in Ischemic Heart Disease. In Hypertension: A Companion to Braunwald's Heart Disease. 3<sup>rd</sup> ed. 2017;288-297.
5. Dietrich E, Michaudet C, **Smith SM**†. Osteoarthritis. In: Katz M, Matthias K, Chisholm-Burns MA. Pharmacotherapy Principles & Practice Study Guide: A Case-Based Care Plan Approach. 4<sup>th</sup> ed. New York, NY: McGraw-Hill; 2016;239-240.
6. Carris N, **Smith SM**, Gums JG. Osteoarthritis. In: Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT. Pharmacotherapy Principles & Practice. 4<sup>th</sup> ed. New York, NY: McGraw-Hill; 2016:889-899.
7. Dietrich E, **Smith SM**, Gums JG. Cushing's Syndrome. In: Schwinghammer TL, Koehler JM. Pharmacotherapy Casebook: A Patient-Focused Approach. 9<sup>th</sup> ed. New York, NY: McGraw-Hill; 2014:88-1-88-3.
8. Dietrich E, **Smith SM**, Gums JG. Adrenal Gland Disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach. 9<sup>th</sup> ed. New York, NY: McGraw-Hill; 2014:1217-1236.
9. Trinkley KE, **Smith SM**. Applying Literature to Patient Care. In: Aparasu RR, Sherer JT, Bentley JP. Principles of Research Design and Drug Literature Evaluation. 1<sup>st</sup> ed. Boston, MA: Jones & Bartlett; 2014:323-335.
10. **Smith SM**, Vogel Anderson K. Adrenal and Pituitary Disorders. In: Dong BJ, Elliott DP, eds. Ambulatory Care Self-Assessment Program, 2014 Book 1. Endocrinology/Rheumatology. Lenexa, KS: American College of Clinical Pharmacy, 2014:92-120.
11. **Smith SM**, Gums JG, Dietrich E. Osteoarthritis. In: Katz M, Matthias K, Chisholm-Burns MA. Pharmacotherapy Principles & Practice Study Guide: A Case-Based Care Plan Approach. 3<sup>rd</sup> ed. New York, NY: McGraw-Hill; 2013;265-7.
12. **Smith SM**, Dietrich E, Gums JG. Osteoarthritis. In: Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT. Pharmacotherapy Principles & Practice. 3<sup>rd</sup> ed. New York, NY: McGraw-Hill. 2013;1041-53.
13. **Smith SM**, Gums JG. Cushing's Syndrome. In: Schwinghammer TL, Koehler JM. Pharmacotherapy Casebook: A Patient-Focused Approach. 8<sup>th</sup> ed. New York: McGraw-Hill; 2011: 233-5.
14. **Smith SM**, Gums JG. Adrenal Gland Disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach. 8<sup>th</sup> ed. New York: McGraw-Hill; 2011: 1327-44.



15. **Smith SM**. Osteoarthritis. In: Chisholm-Burns MA, Katz M, Matthias K. *Pharmacotherapy Principles & Practice Study Guide: A Case-Based Care Plan Approach*. 1<sup>st</sup> ed. New York, NY: McGraw-Hill; 2011: 247-9.
16. **Smith SM**, Epstein BJ, Gums JG. Osteoarthritis. In: Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT. *Pharmacotherapy Principles & Practice*. 2<sup>nd</sup> ed. New York, NY: McGraw-Hill; 2010: 997-1009.

### Non-Peer-Reviewed

1. **Smith SM**. At the Forefront of U.S. Health and Policy: The 2014-206 National Academy of Medicine Fellowship. *ACCP Report* 2016;35(11):14-15. Available electronically at: <http://www.accp.com/docs/report/1116.pdf>.

### Abstracts/Presentations

1. Wokhlu A, Gong Y, Cooper-DeHoff RM, **Smith SM**, Handberg EM, Pepine CJ. Relationship between diastolic blood pressure and all-cause mortality with lower systolic blood pressure among hypertensive coronary artery disease patients: Long-term follow-up of the US cohort of the International Verapamil-SR-Trandolapril Study (INVEST). Accepted for Moderated Poster Presentation for American College of Cardiology (ACC) 2017 Annual Scientific Session & Expo, March 17-19, 2017, Washington D.C., USA.
2. Deiningner KM, Hirsch JD, Graveline SA, Feist A, **Smith SM**, Reich JA, LaFleur J, Ambardekar AV, Lindenfeld J, Aquilante CL. Relationship between patient-perceived treatment burden and medication adherence in heart transplant patients. Accepted for oral presentation at the International Society for Heart & Lung Transplantation (ISHLT) 2017 Annual Meeting and Scientific Sessions, April 5-8, 2017, San Diego, CA, USA.
3. Hwang AY, Dave C, **Smith SM**. Use of Medications that Potentially Interfere with Blood Pressure Control among Patients with Resistant Hypertension on  $\geq 4$  Antihypertensive Drugs. Poster presentation at 2016 American College of Clinical Pharmacy Annual Meeting, October 24<sup>th</sup>, 2016, Hollywood, FL, USA.
4. Aquilante CL, Hirsch JD, LaFleur J, Reich J, **Smith SM**. Patient-perceived treatment burden following heart transplantation. Platform presentation at 2016 Skaggs Biomedical Research Symposium, August 4-5, 2016, Pocatello, ID, USA.
5. Deiningner KM, Reich JA, Hirsch JD, Graveline S, LaFleur J, **Smith SM**, Ambardekar AV, Lindenfeld J, Aquilante CL. Qualitative assessment of patient-perceived treatment burden following cardiac transplantation. Poster presentation at:
  - a. 2016 American Transplant Congress, June 11-15, 2016, Boston, MA, USA (Original presentation). Abstract published in *Am J Transplant* 2016;16(suppl 3):553 and <http://www.atcmeetingabstracts.com/abstract/qualitative-assessment-of-patient-perceived-treatment-burden-following-cardiac-transplantation/>.
  - b. 2016 American College of Clinical Pharmacy Annual Meeting, October 23-25, 2016, Hollywood, FL, USA (Encore presentation).
6. **Smith SM**, Hwang AY, Dave C. Trends in antihypertensive medication use among U.S. patients with resistant hypertension, 2008-2013. Poster presentation at:
  - a. 2016 American Society of Hypertension Annual Meeting, May 14<sup>th</sup>, 2016, New York, NY, USA. Abstract available in *J Am Soc Hypertens* 2016;10(4S):e36 (Original presentation)
  - b. 2016 Community Health & Family Medicine Research Showcase, June 23<sup>rd</sup>, 2016, Gainesville, FL (Encore presentation)

- c. 2016 American College of Clinical Pharmacy Annual Meeting, October 25<sup>th</sup>, 2016, Hollywood, FL, USA (Encore presentation)
7. Farland M, Ryan S, Ramachandran N, **Smith SM**. An electronic gallery walk in a high enrollment pharmacy population health course. Technology Showcase Demonstration and Poster Presentation at Team-Based Learning Collaborative 2016 Annual Meeting, March 3-5, 2016, Albuquerque, NM, USA.
8. Tsai T, Kroehl M, **Smith SM**, Thompson A, Trinkley K. Efficacy and safety of twice- versus once-daily dosing of lisinopril for the treatment of hypertension. Poster presentation at the 2015 American Society of Health-System Pharmacists (ASHP) Midyear Annual Meeting, December 7<sup>th</sup>, 2015, New Orleans, LA, USA.
9. Carris NW, **Smith SM**, Taylor JR, Sando K, Powell J, Hwang A, Gums JG, Dietrich E, Vogel Anderson K. Anticoagulation-related quality of life associated with extended-interval monitoring: A pre-specified analysis of the FADE-OUT study. Poster presentation at the 2015 American College of Clinical Pharmacy (ACCP) Global Conference on Clinical Pharmacy, October 20<sup>th</sup>, 2015, San Francisco, CA, USA. Abstract published in *Pharmacotherapy* 2015;35(11):e271.
10. Dietrich E, **Smith SM**, Gums JG. A Novel Revenue-Generating Pharmacy-Led Transitions of Care Program. Platform & Poster presentation at the 2015 American College of Clinical Pharmacy (ACCP) Global Conference on Clinical Pharmacy, October 19<sup>th</sup>, 2015, San Francisco, CA, USA. Abstract published in *Pharmacotherapy* 2015;35(11):e223-e224.
11. Trujillo JM, Malhotra JV, **Smith SM**, Franson KL. Establishing inter-rater reliability of two patient-centered communication rubrics with international faculty evaluators. Poster presentation at the 2015 American Association of Colleges of Pharmacy (AACP) Annual Meeting, July 11-15, 2015, Washington D.C., USA.
12. Trujillo JM, Franson KL, **Smith SM**, Trujillo TC. Establishing the inter-rater reliability of two patient-centered communication evaluation rubrics. Poster presentation at the 2015 American Association of Colleges of Pharmacy (AACP) Annual Meeting, July 11-15, 2015, Washington D.C., USA.
13. Shute K, Kodsi B, Samraj G, Malaty J, Carris N, **Smith SM**. Establishing and integrating a multidisciplinary anticoagulation clinic into an academic-based residency program. Scholarly Topic Roundtable Presentation at the Society of Teachers of Family Medicine 2015 annual meeting, April 25<sup>th</sup>-29<sup>th</sup>, 2015, Orlando, FL, USA.
14. Huo T, **Smith SM**, Pepine CJ, Gong Y, Handberg E, Gulati M, Bairey Merz CN, Cooper-DeHoff RM, Chi YY. Data and statistical challenges in pooled analysis of clustered survival data from multiple clinical studies. Poster presentation at the 70<sup>th</sup> Deming Conference on Applied Statistics, December 8-12, 2014, Atlantic City, NJ, USA.
15. **Smith SM**, Ghushchyan V, Libby AM. Direct medical expenditures and healthcare utilization associated with resistant hypertension in the United States. Poster presentation at the American Heart Association 2014 Scientific Sessions, November 16, 2014, Chicago, IL, USA. Abstract available in *Circulation* 2014;130:A20369 and [http://circ.ahajournals.org/content/130/Suppl\\_2/A20369.abstract](http://circ.ahajournals.org/content/130/Suppl_2/A20369.abstract).
16. **Smith SM**, Huo T, Gong Y, Handberg E, Gulati M, Bairey Merz CN, Pepine CJ, Cooper-DeHoff RM. Mortality risk associated with apparent treatment-resistant hypertension among women. Poster presentation at:
  - a. American Heart Association 2014 Scientific Sessions, November 16, 2014, Chicago, IL, USA. Abstract available in *Circulation* 2014;130:A17677 and [http://circ.ahajournals.org/content/130/Suppl\\_2/A17677.abstract](http://circ.ahajournals.org/content/130/Suppl_2/A17677.abstract). (Original presentation)
  - b. UF College of Medicine 2015 Celebration of Research, February 9, 2015, Gainesville, FL, USA. (Encore presentation)

17. **Carris NW**, Taylor J, Anderson KV, Sando K, Spinelli A, Elliott J, Powell J, Pierini DC, Cogan P, **Smith SM**, Gums JG, Dietrich E. Feasibility of extended duration follow-up for patients receiving warfarin. Poster presentation at:
  - a. American College of Clinical Pharmacy 2014 Annual Meeting, October 14, 2014, Austin, TX, USA. Abstract available in *Pharmacotherapy* 2014;34(10):e254. (Original presentation)
  - b. UF College of Medicine 2015 Celebration of Research, February 9, 2015, Gainesville, FL, USA. (Encore presentation)
18. **Smith SM**, Hasan M, Huebschmann A, Penaloza R, Schorr-Ratzlaff W, Sieja A, Trinkley K. Physician engagement and acceptance of collaborative treatment of hypertension in primary care. Platform and poster presentation at the American College of Clinical Pharmacy 2014 Annual Meeting, October 13, 2014, Austin, TX, USA. (2<sup>nd</sup> runner up for 2014 ACCP Annual Meeting "Great Eight" Best Paper competition). Abstract available in *Pharmacotherapy* 2014;34(10):e182.
19. Hirsch J, Watanabe J, LaFleur J, **Smith SM**, Aquilante C, Libby A. Medication Regimen Complexity Index (MRCI): The Skaggs Research Cascade. Poster presentation at the 2014 Skaggs Biomedical Research Symposium, August 14, 2014, Missoula, MT, USA.
20. Aquilante CL, Hirsch JD, LaFleur J, Libby AM, Lindenfeld J, Page RL, **Smith SM**. Predictors of medication non-adherence following heart transplantation: the role of medication regimen complexity and patient-perceived treatment burden. Poster presentation at the 2014 Skaggs Biomedical Research Symposium, August 14, 2014, Missoula, MT, USA.
21. **Smith SM**, Ghushchyan V, Libby AM. Health-related quality of life in persons with apparent treatment-resistant hypertension taking at least four antihypertensives. Poster presentation at:
  - a. American Society of Hypertension 2014 Annual Meeting, May 18, 2014, New York, NY, USA. Abstract available in *J Am Soc Hypertens* 2014;8(4S):e84. (Original presentation)
  - b. American College of Clinical Pharmacy 2014 Annual Meeting, October 13, 2014, Austin, TX, USA. (Encore presentation)
22. Borja-Hart N, **Smith SM**, Wooten A, Lukawski T, Epstein BJ. Simulating Framingham risk reductions to assess applicability as a global study endpoint: Report from the P.A.T.H. Steering Committee. Poster presentation at the American Society of Health-System Pharmacists (ASHP) 2012 Annual Midyear Meeting, December 2012, Las Vegas, NV, USA. Abstract available at: <http://www.ashp.org/DocLibrary/Abstract-Archive/MCM12-Poster-Abstracts.pdf>.
23. **Smith SM**, Borja-Hart N, Wooten A, Epstein BJ. Discordance between regression-derived and ATP III table-derived Framingham 10-year risk. Poster presentation at the American College of Clinical Pharmacy 2012 Annual Meeting, October 24<sup>th</sup>, 2012, Kissimmee, FL. Abstract available in *Pharmacotherapy* 2012;32(10):e184-e185.
24. Trinkley K, Moore G, Nair K, **Smith SM**. A reimbursement model through a University's self-insurance for ambulatory care clinical pharmacy services. Poster presentation at the American College of Clinical Pharmacy 2012 Annual Meeting, October 24<sup>th</sup>, 2012, Kissimmee, FL. Abstract available in *Pharmacotherapy* 2012;33(10):e253.
25. **Smith SM**, Borja-Hart NL, Wooten A, Lukawski T, Shah NK, Epstein BJ. Simulating Framingham risk reductions to assess applicability as a global study endpoint: Report from the P.A.T.H. Steering Committee. Poster presentation at the Florida Society of Health-System Pharmacists (FSHP) 2012 Annual Meeting, August 2012, Orlando, FL, USA.
26. Shah NK, Epstein BJ, Lo M, Ashfaq U, Satish P, **Smith SM**, Nichols WW. Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling compared to atenolol: The CENTRAL Study.

Poster presentation at the University of Florida Annual College of Pharmacy Research Showcase, February 2011, Gainesville, FL, USA.

27. **Smith SM**, Antonio S, Barkley P, Dequesada A, Dodd V, Drucker J, Giuliano A, Manion E, Obesso D, Cook RL. The HPV Oral Prevalence Investigation (HOP-IN) Study: Rationale & Design. Poster presentation at Emerging Pathogen Institute 2011 Research Day, February 10<sup>th</sup>, 2011, Gainesville, FL, USA.
28. Gums JG, **Smith SM**, Tyrol K, Patel R, Adelman DN, Ng V, Pratt LE. A national antibiotic surveillance program: 3 year follow-up study. Poster presentation at ICAAC 50<sup>th</sup> Annual Meeting, September 13<sup>th</sup>, 2010, Boston, MA, USA.
29. **Smith SM**, Gums JG, Alessandrini J, Kaufman D, Ng V. Can an individualized educational stewardship program affect prescribing patterns and reduce antimicrobial resistance? Poster presentation at IDSA 47<sup>th</sup> Annual Meeting, October 30<sup>th</sup>, 2009, Philadelphia, PA, USA.
30. Nichols WW, **Smith SM**, Epstein BJ. Elevated wasted left ventricular pressure effort and reflected wave amplitude in treated hypertensives. Poster presentation at American Society of Hypertension Annual Meeting, San Francisco, CA. May 7<sup>th</sup>, 2009. Abstract available in *J Clin Hyperten* 2009;11(4):A18.
31. **Smith SM**, Anderson SD, Cooper-DeHoff RM, Feng H, Bailey K, Turner ST, Chapman A, Johnson JA, Gums JG. Correlation of thiazide-induced potassium changes with glucose. Poster presentation at:
  - a. ACCP 2008 Annual Meeting, Louisville, KY. October 21<sup>st</sup>, 2008. Abstract available in *Pharmacotherapy* 2008;28:138e. (Original presentation)
  - b. ACCP 2009 Spring Meeting, Orlando, FL. April 25<sup>th</sup>, 2009. (Encore presentation)
  - c. UF College of Medicine Research Showcase, Gainesville, FL. April 28<sup>th</sup>, 2009. (Encore presentation)
32. **Smith SM**, Gums JG, Greaves R, Ng V. Outcomes Associated with the Implementation of a National Antibiotic Surveillance Program. Poster presentation at:
  - a. ICAAC/IDSA 2008 Annual Meeting, Washington, D.C. October 26<sup>th</sup>, 2008. (Original presentation)
  - b. ACCP 2009 Spring Meeting, Orlando, FL. April 25<sup>th</sup>, 2009. (Encore presentation)
  - c. UF College of Medicine Research Showcase, Gainesville, FL. April 28<sup>th</sup>, 2009. (Encore presentation)
33. **Smith SM**, Gums JG, Jermaine C, Ranka S. The Implications of Phenotypic Clustering on Predicting Future Trends of Antimicrobial Resistance Patterns. Poster presentation at:
  - a. ICAAC/IDSA 2008 Annual Meeting, Washington, D.C. October 26<sup>th</sup>, 2008. (Original presentation)
  - b. ACCP 2009 Spring Meeting, Orlando, FL. April 25<sup>th</sup>, 2009. (Encore presentation)

## **TEACHING**

### **University of Florida**

#### *School of Pharmacy*

Pharmacy & Population Health (PHA 5007). 1<sup>st</sup> year PharmD students. Fall semesters (2 credit hours). Course leader (2015 – present). This 5-week course uses team-based learning to provide an introduction to population health concepts and how pharmacists engage in population health activities.

Pharmacotherapy VI (PHA 5788). 4<sup>th</sup> year PharmD students. Spring semesters (2 credit hours). Overall course coordinator (2015 – present). Section co-coordinator (2008 – 2011). This 8-week course serves as the capstone for the PharmD curricula, where students present cases and evidence-based therapeutic plans from patients seen during their rotations.

Ambulatory Care Clinical Rotations. July 2008 – June 2011; March 2014 – June 2016. Precept 15-18 students/year during 8-week Ambulatory Care required rotation or 4-week Ambulatory Care elective rotation.

Pharmacotherapy II. 2008 – 2011. Lecturer (Glaucoma, Depression).

Pharmacotherapy III. 2008 – 2011. Lecturer (Skin/soft tissue infections, Upper/Lower respiratory tract infections).

Skills Lab. 2007. Teaching Assistant.

Pharmacotherapy V. 2007. Lecturer (Vancomycin Pharmacokinetics).

#### *School of Medicine – Physician Assistant Program*

Pharmacotherapy. 2008 – 2011. Lecturer (Hypertension, Heart Failure, Diabetes, Infectious Diseases & Antibiotics, Antiviral/Antifungal/Antiparasitic Pharmacotherapy, Geriatric Pharmacotherapy, GI Pharmacotherapy, COPD/Asthma).

## **University of Colorado**

#### *School of Pharmacy*

PHRD 5965, Patient-centered Communication 2. Course Coordinator (2013 – 2014); Approximately 160 students/semester; Course Coordinator and lectured approximately 4 hours/semester on prescription counseling and medication adherence assessment/motivational interviewing.

PHRD 8700, Advanced Pharmacy Practice Experience. May 2012 – December 2013. Precepted 1-2 students per 6-week rotation through Internal Medicine clinic.

#### *School of Medicine*

Ambulatory Care Clinical Elective. 2012 – 2013; Facilitated pharmacotherapy case discussions with 3<sup>rd</sup> year medical students for ~1 hour/month

## **Residents/Fellows** (reverse chronological order)

1. Andrew Hwang, PharmD (Family Medicine Fellow – UF), 2015 – 2017
2. Nick Carris, PharmD, BCPS (Family Medicine Fellow - UF), 2014 – 2015
3. Michaela Hasan, PharmD (PGY-1 Community Pharmacy - CU), 2013 – 2014
4. Allie Schroeder, PharmD (Clinical Outcomes Fellow – CU/Kaiser Permanente), 2013 – 2014
5. William (Mackie) King IV, PharmD, BCPS (PGY-2 Ambulatory Care - CU), 2012 – 2013
6. Kelli Metz, PharmD (Pharmaceutical Outcomes Research Fellow - CU), 2012 – 2014
7. Kimberly Swanson, PharmD (PGY-1 Community Pharmacy - CU), 2012 – 2013
8. Angie Thompson, PharmD, BCPS (PGY-2 Ambulatory Care - CU), 2011 – 2012

## **CLINICAL ACTIVITY**

2014 – 2016

Co-Director, Anticoagulation and Pharmacotherapy Consult Services, Family Medicine at Main St, UF Health

2012 – 2014	Director, Hypertension Clinic, University Medicine Lowry and University Medicine Anschutz, Division of Internal Medicine, Department of Medicine, School of Medicine, University of Colorado
2011 – 2014	Director, Pharmacotherapy Consult Service, University Medicine Lowry, Division of Internal Medicine, Department of Medicine, School of Medicine, University of Colorado
2012 – 2013	Member, PCMH Team of Champions, University Medicine, University of Colorado Hospital
2011 – 2012	Co-Director, <i>RxConsult</i> (CU self-insurance clinical pharmacy service), University of Colorado
2008 – 2011	Associate Director, Pharmacotherapy Consult Service, Family Medicine at 4 <sup>th</sup> Ave, University of Florida
2007 – 2008	Hospital Practice Resident, NF/SG Veteran's Affairs Hospital, Gainesville, FL

### **SPEAKING ENGAGEMENTS** (reverse chronological order)

1. *The Rise and Fall of 'Resistant' Blood Pressure: Adverse Consequences & Clinical Approaches to Difficult-to-Treat Hypertension*, College of Pharmacy, University of Florida, July 2016.
2. *Pharmacist-Physician Collaboration for Uncontrolled Treatment-Resistant Hypertension*. Community Health & Family Medicine Research Day, University of Florida, June 2016.
3. *Adverse Outcomes and Clinical Approaches to Resistant Hypertension*. Pharmacotherapy & Translational Research Seminar Series, University of Florida, March 2016.
4. *2015 New Investigator Award Seminar: Resistant Hypertension: Determinants, Outcomes, and Approaches to Blood Pressure Intransigence*, American College of Clinical Pharmacy Global Conference, San Francisco, CA, October 2015.
5. Fellowship Discussion, Student Residency Forum, College of Pharmacy, University of Florida, September 2015.
6. Introductory Professional Pharmacy Experience Panel Discussion, College of Pharmacy, University of Florida, November 2014.
7. *Physician Engagement and Acceptance of Collaborative Treatment of Hypertension in Primary Care*, American College of Clinical Pharmacy Annual Meeting, Austin, TX, October 2014.
8. *Resistant Hypertension: The Adverse Impact of Blood Pressure Intransigence*, Pharmacotherapy & Translational Research Seminar Series, University of Florida, November 2013
9. *Resistant Hypertension: Current Treatment and the Road Ahead*, Pharmacotherapy & Translational Research Seminar Series, University of Florida, November 2012
10. *Tuberculosis Screening and Testing Policies Among U.S. Universities: A cross-sectional survey of university student health care center directors*, Public Health Research Day, College of Public Health & Health Professions, University of Florida, July 2011
11. *Central Aortic Blood Pressure Effects of Antihypertensive Therapies*, Pharmacotherapy & Translational Research/Center for Pharmacogenomics Seminar Series, University of Florida, April 2011
12. *Thiazide-induced hypokalemia and hyperglycemia*, North Central Florida Society of Health Systems Pharmacists (NCFSP) Meeting, Gainesville, FL, June 2010

13. *Antimicrobial Surveillance: Hindsight is not 20/20*, Pharmacotherapy & Translational Research/Center for Pharmacogenomics Seminar Series, University of Florida, March 2010
14. *Thiazide-induced hypokalemia and dysglycemia: Comparing emergent data with old assumptions*, Pharmacotherapy & Translational Research/Center for Pharmacogenomics Seminar Series, University of Florida, May 2009
15. *Outpatient Management of Chronic Heart Failure*, UF 2009 Primary Care Symposium CE Program, Gainesville, FL
16. *The changing landscape of heart failure: Translating emerging data into practice*, Ken Finger 2008 CE Program, University of Florida, Gainesville, FL, June 2008

## **SERVICE**

### **University of Florida (2014 – present)**

#### *College of Pharmacy*

- 2016 – Professionalism Committee, *Member*
- 2016 – Faculty Awards Committee, *Member*
- 2015 Search Committee for Pharmaceutical Outcomes & Policy Department Chair, *Member*
- 2015 28<sup>th</sup> Annual COP Research Showcase, *Oral Presentation Judge*
- 2015 2015 Clinical Practice Strategic Planning Task Force (COP), *Member*
- 2014 – 2016 APPE Student Issues *ad hoc* committee, *Member*
- 2014 – 2015 Admissions Committee, *Member*

#### *College of Medicine*

- 2015 – CHFMs Scholars Program, *Mentor*
- 2015 – 2016 Search Committee for CHFMs Vice Chair for Research, *Member*
- 2014 – 2016 CHFMs Research/QI Committee (COM), *Member*

#### *Clinical & Translational Science Institute*

- 2015 – Personalized Medicine Program Education Advisory Board, *Member*

### **University of Colorado (2011 – 2014)**

- 2012 – 2014 Honors Program Committee, *Member*
- 2012 – 2014 Distance Degree Program Committee, *Member*
- 2013 – 2014 NTPD Instructor Search Committee (ad hoc), *Chair*
- 2013 – 2014 Faculty & Staff Accreditation Committee, *Member*

## **PROFESSIONAL ACTIVITY AND PUBLIC SERVICE**

### **Membership and service in professional organizations**

- American Society of Hypertension, Member 2012 – present;  
Member, Task Force for ASH Hypertension Specialists Designation Status for Qualified Non-physician Healthcare Providers (2013 – 2014)

Founding Member, Examination Committee for ASH Certified Hypertension Clinician (2014 – present)  
Item Writer, ASH Certified Hypertension Clinician Examination (2015 – present)

American Heart Association, Member, 2012 – present  
Member, Council for Hypertension (formerly, High Blood Pressure Research), 2012 – present  
Member, Council on Quality of Care and Outcomes Research, 2015 – 2016

American College of Clinical Pharmacy, Member 2007 – present  
Member, Ambulatory Care PRN (2008 – present)  
Member, Research Process Committee (2015 – present)  
Member, Cardiology PRN (2011 – present)  
Member, Infectious Diseases PRN (2008 – 2011)

National Lipid Association, Member 2011 – 2014

American Association of Colleges of Pharmacy, Member, Pharmacy Practice Session, 2011 – present

National Interdisciplinary Primary Care Practice-Based Research Network, Member 2008 – 2011, 2014 – present

American Society of Health-Systems Pharmacists, Member 2007-2009

American Pharmacists Association, Member 2005 – 2008, 2011 – 2014

## Editorial Boards

2016 – present Editorial Board Member, *Pharmacotherapy*

## Journal Referee

2008 – present *Annals of Pharmacotherapy*  
2009 – present *Expert Opinion on Drug Metabolism*  
2011 – present *Pharmacist's Letter*  
2011 – present *Pharmacotherapy*  
2013 – present *Therapeutic Advances in Cardiovascular Diseases*  
2013 – present *Diabetes Research and Clinical Practice*  
2013 – present *American Journal of Hypertension*  
2014 – present *PLoS One*  
2015 – present *Journal of Human Hypertension*  
2015 – present *Journal of Clinical Hypertension*  
2015 – present *Obesity*  
2016 – present *American Journal of Preventive Medicine*

## Other

2014 – 2016 Managing Editor, *PharmaNote*® Monthly Pharmacy Newsletter, Departments of Pharmacotherapy & Translational Research and Community Health & Family Medicine, Colleges of Pharmacy and Medicine, University of Florida; available at: <http://pharmacy.ufl.edu/pharmanote>

2013 – 2014 Expert Content Reviewer, *Osteoarthritis* chapter, PSAP-VIII Book 4 *Chronic Illnesses* (ACCP)



- 2012 – 2014 Editor-in-Chief, *Materia Medica*, Monthly Pharmacy Newsletter, Departments of Clinical Pharmacy and Medicine (Division of General Internal Medicine), Schools of Pharmacy and Medicine, University of Colorado
- 2008 – 2011 Assistant Editor, *PharmaNote*® Monthly Pharmacy Newsletter, Departments of Pharmacotherapy & Translational Research and Community Health & Family Medicine, Colleges of Pharmacy and Medicine, University of Florida

## **PROFESSIONAL DEVELOPMENT**

### **Coursework**

*Applied Cost-Effectiveness Analyses* (PHSC 7611), University of Colorado, Fall 2012

### **Conferences/Seminars/Workshops**

- American Association of Colleges of Pharmacy (AACP) Institute, *Teaching Essentials*, Leesburg, VA, May 20-22, 2013
- Colorado Mentoring Training (CO-Mentor) Program, Colorado Clinical and Translational Sciences Institute (CCTSI), University of Colorado, 2012-13
- AcademyHealth Health Policy Orientation, Washington, D.C., October 27<sup>th</sup>-29<sup>th</sup>, 2014
- IOM Population Health Improvement Roundtable Workshop, *Training in Interdisciplinary Population Health Science: A Vision for the Future*, Washington, D.C., June 1<sup>st</sup>, 2015
- IOM Population Health Improvement Roundtable Workshop, *Applying a Health Lens II: The Role and Potential of the Private Sector to Improve Economic Well-Being and Community Outcomes*, Irvine, CA, June 4<sup>th</sup>-5<sup>th</sup>, 2015
- IOM Population Health Improvement Roundtable Workshop, *Metrics that Matter for Population Health Action: A Workshop*, Oakland, CA, July 30<sup>th</sup>-31<sup>st</sup>, 2015
- IOM Population Health Improvement Roundtable Workshop, *Advancing the Science to Improve Population Health*, Washington D.C., September 30<sup>th</sup>-October 1<sup>st</sup>, 2015
- NAM (formerly IOM) Board on Population Health and Public Health Practice Spring Meeting, Washington D.C., May 24-25, 2016
- NAM Board on Health Sciences Policy Spring Meeting, Washington D.C., June 8, 2016
- NAM Population Health Improvement Roundtable Workshop, *Community Violence as a Population Health Issue*, Brooklyn, NY, June 16, 2016
- NAM Population Health Improvement Roundtable Workshop, *Building Sustainable Financing Structures for Population Health*, Washington D.C., October 19<sup>th</sup>, 2016